{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-001795","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2023-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.300872+00:00","generated_at":"2026-06-20T14:16:27.682814+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Immix Biopharma subsidiary Nexcella raises ~$650k in private placement at $6.49/share","bullets":["Nexcella entered share purchase agreements with accredited investors for 100,152 shares at $6.49/share.","Gross proceeds of approximately $650,000; after closing, Nexcella has 6,357,444 shares outstanding.","Offering exempt under Section 4(a)(2) and Rule 506 of Regulation D; shares are restricted securities.","Shares subject to drag-along rights and potential 365-day lock-up upon any future IPO of the subsidiary."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-001795","json":"https://secwatch.observer/filing/0001493152-23-001795.json","markdown":"https://secwatch.observer/filing/0001493152-23-001795.md","text":"https://secwatch.observer/filing/0001493152-23-001795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315223001795/0001493152-23-001795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315223001795/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T14:16:27.682814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d5df17b3a21cc4921b8311ccd3b872668d6d6856","claim":"Immix Biopharma, Inc. entered into Purchase Agreements with certain accredited investors valued at approximately $650,000 (effective 2023-01-12).","evidence_excerpt":"On January 12, 2023, Nexcella, Inc. (“Nexcella”), a subsidiary of Immix Biopharma, Inc. (collectively, the “Company”) entered into share purchase agreements (the “Purchase Agreements”) with certain accredited investors for their purchase of an aggregate 100,152 shares of Nexcella’s common stock at a purchase price of $6.49 per share, for gross proceeds of approximately $650,000 (the “Private Placement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1873835/000149315223001795/0001493152-23-001795-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"approximately $650,000"},{"label":"Effective","value":"2023-01-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}